SCHEMBL401199

SCHEMBL401199

NNC(=O)c1cccc(Br)c1

nearest known ligand 0.64

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.64
ALDH1A1 P00352 4/20 0.63
KDM4E B2RXH2 3/20 0.63
SMN1; SMN2 Q16637 4/20 0.63
NPC1 O15118 4/20 0.63
RAB9A P51151 3/20 0.63
PARP1 P09874 1/20 0.62
OGG1 O15527 1/20 0.59
MEN1 O00255 3/20 0.57
KMT2A Q03164 3/20 0.57
CYP1A2 P05177 1/20 0.57
CYP2C19 P33261 1/20 0.57
TP53 P04637 1/20 0.56
HTT P42858 1/20 0.56
AOC2 O75106 1/20 0.54
LMNA P02545 1/20 0.54
POLB P06746 1/20 0.54
GAA P10253 1/20 0.54
MAPT P10636 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL77384 0.85 ALDH1A1 (0.76) L3MBTL1ALDH1A1KDM4ESMN1; SMN2NPC1
SCHEMBL17236166 0.83 SMN1; SMN2 (0.77) L3MBTL1ALDH1A1SMN1; SMN2NPC1RAB9A
SCHEMBL17336774 0.83 KDM4E (0.64) L3MBTL1ALDH1A1KDM4ESMN1; SMN2NPC1
SCHEMBL31305679 0.83 KDM4E (0.64) L3MBTL1ALDH1A1KDM4ESMN1; SMN2NPC1
SCHEMBL18377765 0.83 L3MBTL1 (0.68) L3MBTL1ALDH1A1KDM4ESMN1; SMN2NPC1
SCHEMBL17200636 0.82 NPC1 (0.60) L3MBTL1ALDH1A1KDM4ESMN1; SMN2NPC1
SCHEMBL7377549 0.82 PARP1 (0.55) L3MBTL1ALDH1A1KDM4ESMN1; SMN2NPC1
SCHEMBL1904111 0.81 ALDH1A1 (0.70) L3MBTL1ALDH1A1KDM4ESMN1; SMN2NPC1
SCHEMBL5426936 0.81 L3MBTL1 (0.75) L3MBTL1ALDH1A1KDM4ESMN1; SMN2NPC1
SCHEMBL30618513 0.81 L3MBTL1 (0.75) L3MBTL1ALDH1A1KDM4ESMN1; SMN2NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 271 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11398630-B2 Method of generating energy from a hydrazide containing anode fuel, and fuel cell IOWA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) 2022-07-26 US claimed
US-20210005900-A1 METHOD OF GENERATING ENERGY FROM A HYDRAZIDE CONTAINING ANODE FUEL, AND FUEL CELL IOWA STATE UNIVERSITY RESEARCH FOUNDATION, INC. 2021-01-07 US claimed
US-10040741-B2 Method for manufacturing high purity glycol based compound SAMSUNG DISPLAY CO., LTD. (KR) 2018-08-07 US claimed
US-20160297732-A1 METHOD FOR MANUFACTURING HIGH PURITY GLYCOL BASED COMPOUND SAMSUNG DISPLAY CO., LTD. (KR) 2016-10-13 US claimed
US-20030105140-A1 Substituted indole-2-carboxylic acid benzylidene-hydrazides and analogs as activators of caspases and inducers of apoptosis and the use thereof CYTOVIA, INC. 2003-06-05 US claimed
WO-2002102301-A2 SUBSTITUTED INDOLE-2-CARBOXYLIC ACID BENZYLIDENE-HYDRAZIDES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF CYTOVIA, INC. (US) 2002-12-27 WO claimed
US-20020128292-A1 Substituted indole-2-carboxylic acid benzylidene-hydrazides and analogs as activators of caspases and inducers of apoptosis and the use thereof CYTOVIA, INC. 2002-09-12 US claimed
CN-86105682-A Novel benzamides, process for their preparation and their use in therapy 1987-02-04 CN claimed
US-12509544-B2 Aqueous binder formulation BASF SE (DE) 2025-12-30 US disclosed
EP-4130195-B1 COMPOSITION AND LIGHT-EMITTING ELEMENT CONTAINING SAME SUMITOMO CHEMICAL CO (JP) 2025-09-03 EP disclosed
CN-116113635-B Spiro compounds as melanocortin 4 receptor antagonists and uses thereof 辉瑞公司 2025-03-18 CN disclosed
US-20250084084-A1 Crystalline form of (2R)-2-(5-fluoro-2-methoxypyridin-4-yl)-1-[(2S)-7-methyl-6-(pyrimidin-2-yl)-3,4-dihydro-1H-spiro[1,8-naphthyridine-2,3-pyrrolidin]-1-yl]propan-1-one PFIZER INC. (US) 2025-03-13 US disclosed
EP-4144792-B1 PARTICULATE WATER-ABSORBENT RESIN COMPOSITION, ABSORBENT BODY AND ABSORBENT ARTICLE SUMITOMO SEIKA CHEMICALS (JP) 2025-01-08 EP disclosed
EP-4144803-B1 WATER ABSORBENT RESIN COMPOSITION, ABSORBENT, AND ABSORBENT ARTICLE SUMITOMO SEIKA CHEMICALS (JP) 2024-12-25 EP disclosed
CN-1021441-C PROCESS FOR PREPARATION OF NEW BENZAMIDES ILE DE FRANCE (FR) 1993-06-30 CN disclosed
US-5120347-A Pre and postemergence ROHM AND HAAS COMPANY (US) 1992-06-09 US disclosed
WO-1989006125-A1 4-ARALKYL-5-SUBSTITUTED-1,2,4-TRIAZOLE-5-THIOLS SMITHKLINE BECKMAN CORPORATION (US) 1989-07-13 WO disclosed
EP-0323737-A1 4-Aralkyl-5-substituted-1,2,4-triazole-5-thiols SMITHKLINE BEECHAM CORPORATION (US) 1989-07-12 EP disclosed
EP-0323590-A2 Carbazoyl derivatives ONO PHARMACEUTICAL CO., LTD. (JP) 1989-07-12 EP disclosed
CN-86105682-A Novel benzamides, process for their preparation and their use in therapy 1987-02-04 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250084084-A1 Crystalline form of (2R)-2-(5-fluoro-2-methoxypyridin-4-yl)-1-[(2S)-7-methyl-6-(pyrimidin-2-yl)-3,4-dihydro-1H-spiro[1,8-naphthyridine-2,3-pyrrolidin]-1-yl]propan-1-one CSPP1, PRNP, RPLP2 L3MBTL1 3093/4885ALDH1A1 305/4885KDM4E 1908/4885
US-20020128292-A1 Substituted indole-2-carboxylic acid benzylidene-hydrazides and analogs as activators of caspases and inducers of apoptosis and the use thereof BAD, API5, CASP2 L3MBTL1 1507/4885ALDH1A1 144/4885KDM4E 2887/4885
US-20030105140-A1 Substituted indole-2-carboxylic acid benzylidene-hydrazides and analogs as activators of caspases and inducers of apoptosis and the use thereof BAD, API5, CASP2 L3MBTL1 1507/4885ALDH1A1 144/4885KDM4E 2887/4885
US-12509544-B2 Aqueous binder formulation ADH1C, AKR1C1, AKR1C2 L3MBTL1 2558/4885ALDH1A1 70/4885KDM4E 466/4885
US-10040741-B2 Method for manufacturing high purity glycol based compound GK, GMDS, UGCG L3MBTL1 4699/4885ALDH1A1 87/4885KDM4E 2823/4885
US-20160297732-A1 METHOD FOR MANUFACTURING HIGH PURITY GLYCOL BASED COMPOUND GK, GMDS, UGCG L3MBTL1 4699/4885ALDH1A1 87/4885KDM4E 2823/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.